Tools

LEADER 04785cam a22006497i 4500

001 ssj0001591991;

003 WaSeSS;

005 20220112082112.0;

006 m d ;

007 cr n ;

008 151228s2015 dcua sb 100 0 eng d;

010 a| 2015458702;

020 a| 9780309368575;

020 a| 030936857X;

035 a| (WaSeSS)ssj0001591991;

042 a| lccopycat;

049 a| EREEa| NEHH;

050 00 a| RC270.8b| .P65 2014;

082 00 a| 362.19699/42| 23;

111 2 a| Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer (Workshop)d| (2014 :c| Washington, D.C.)=| ^A1295887;

245 10 a| Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapiesh| [electronic resource] :b| workshop summary /c| Sharyl J. Nass, Jonathan Phillips, and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National Academies.;

260 a| Washington, D.C. :b| The National Academies Press,c| [2015];

300 a| xx, 85 pages :b| illustrations ;c| 23 cm;

504 a| Includes bibliographical references (p. 76-80).;

505 0 a| Molecular biology revolution in cancer diagnosis and treatment -- Challenges in biomarker test development -- Regulatory oversight challenges -- Clinical implementation challenges -- Reimbursement challenges -- Gathering the evidence : innovative clinical trials -- Gathering the evidence : coverage decisions -- Gathering the evidence : databases and registries -- Education and clinical decision support needs.;

506 a| Available only to authorized users.;

520 a| "One of the challenges in treating cancer is the disease's complexity and variation among patients. Cancer manifests differently in each patient, so treatments that are effective in one patient may not be effective in another. As cancer care becomes more personalized, subpopulations of individuals will be given preventive or therapeutic interventions based on their susceptibility to a particular disease or their predicted response to a specific treatment. However, before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of technological, regulatory, and reimbursement issues. To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009. Experts provided presentations on the current state of personalized medicine technology, as well as issues in the validation of, regulation of, and reimbursement for the predictive tests that underpin personalized medicine. Participants discussed the obstacles and possible solutions to further developing and using personalized medicine technologies. This document summarizes the workshop"--c| Publisher's description.;

538 a| Mode of access: World Wide Web;

650 0 a| Cancerx| Genetic aspectsv| Congresses.=| ^A990558;

650 0 a| Biochemical markersv| Congresses.=| ^A1235879;

650 12 a| Biological Markers.?| UNAUTHORIZED;

650 12 a| Neoplasms.=| ^A917584;

650 22 a| Health Policy.=| ^A920924;

650 22 a| Molecular Targeted Therapy.=| ^A1205553;

650 7 a| Biochemical markers.2| fast0| (OCoLC)fst00831950;

650 7 a| Cancerx| Genetic aspects.2| fast0| (OCoLC)fst00845368;

650 7 a| Cancerx| Treatment.2| fast0| (OCoLC)fst00845538;

651 2 a| United States.=| ^A965939;

651 7 a| United States.2| fast0| (OCoLC)fst01204155?| UNAUTHORIZED;

655 0 a| Electronic books.=| ^A491897;

700 1 a| Patlak, Margie.=| ^A1015055;

700 1 a| Nass, Sharyl J.=| ^A875025;

700 1 a| Phillips, Jonathan.=| ^A1094927;

710 2 a| National Cancer Policy Forum (U.S.)=| ^A876199;

710 2 a| Institute of Medicine (U.S.).b| Board on Health Care Services.=| ^A881507;

856 40 z| Full text available from Ebook Central - Academic Completeu| https://ebookcentral.proquest.com/lib/eastcarolina/detail.action?docID=3439842;

947 a| (OCoLC)ocn911511666;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 4423365;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 4423365-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 6/9/2016x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 4423365-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 6/9/2016x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 4423365-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 6/9/2016x| EBOOKz| JERESOURCE;

Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies workshop summary / Sharyl J. Nass, Jonathan Phillips, and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National Academies.

Author/creator	Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer (Workshop)
Format	Electronic
Publication Info	Washington, D.C. : The National Academies Press, [2015]
Description	xx, 85 pages : illustrations ; 23 cm
Supplemental Content	Full text available from Ebook Central - Academic Complete
Subjects	Cancer--Treatment. --United States. --Congresses. Cancer--Genetic aspects. --Congresses. Biochemical markers--Congresses. Biological Markers. Neoplasms. Health Policy. Molecular Targeted Therapy. United States.

Other author/creator	Patlak, Margie.
Other author/creator	Nass, Sharyl J.
Other author/creator	Phillips, Jonathan.
Other author/creator	National Cancer Policy Forum (U.S.)
Other author/creator	Institute of Medicine (U.S.). Board on Health Care Services.
Contents	Molecular biology revolution in cancer diagnosis and treatment -- Challenges in biomarker test development -- Regulatory oversight challenges -- Clinical implementation challenges -- Reimbursement challenges -- Gathering the evidence : innovative clinical trials -- Gathering the evidence : coverage decisions -- Gathering the evidence : databases and registries -- Education and clinical decision support needs.
Abstract	"One of the challenges in treating cancer is the disease's complexity and variation among patients. Cancer manifests differently in each patient, so treatments that are effective in one patient may not be effective in another. As cancer care becomes more personalized, subpopulations of individuals will be given preventive or therapeutic interventions based on their susceptibility to a particular disease or their predicted response to a specific treatment. However, before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of technological, regulatory, and reimbursement issues. To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009. Experts provided presentations on the current state of personalized medicine technology, as well as issues in the validation of, regulation of, and reimbursement for the predictive tests that underpin personalized medicine. Participants discussed the obstacles and possible solutions to further developing and using personalized medicine technologies. This document summarizes the workshop"-- Publisher's description.
Bibliography note	Includes bibliographical references (p. 76-80).
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Genre/form	Electronic books.
LCCN	2015458702
ISBN	9780309368575
ISBN	030936857X

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies workshop summary / Sharyl J. Nass, Jonathan Phillips, and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National Academies.

Click here for more information about this title

Availability